Breaking News

Gannet BioChem Acquires Laysan Bio

Strengthens its capabilities across activated polymer technologies, including PEG reagents and bioconjugation.

Author Image

By: Charlie Sternberg

Associate Editor

Gannet BioChem, a specialty Contract Development and Manufacturing Organization (CDMO) backed by Boston-based private equity firm Ampersand Capital Partners, has acquired Laysan Bio, a life sciences company based in Arab, Alabama. The acquisition strengthens Gannet BioChem’s capabilities across activated polymer technologies, including PEG reagents and bioconjugation while enhancing its ability to support partners from early development through GMP manufacturing. The acquisition also suppo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters